

(138) STN

Connecting via Winsock to STN

State of the art

Welcome to STN International! Enter x:x

LOGINID:sssptal626gms

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3 Jan 29 FSTA has been reloaded and moves to weekly updates
NEWS 4 Feb 01 DKILLIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6 Mar 08 Gene Names now available in BIOSIS
NEWS 7 Mar 22 TOXLIT no longer available
NEWS 8 Mar 22 TRCTHERMO no longer available
NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/CAPLUS and USPATFULL
NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12 Apr 08 "Ask CAS" for self-help around the clock
NEWS 13 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14 Apr 09 ZDB will be removed from STN
NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:57:06 ON 09 MAY 2002

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:57:13 ON 09 MAY 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 7 MAY 2002 HIGHEST RN 412267-09-5

DICTIONARY FILE UPDATES: 7 MAY 2002 HIGHEST RN 412267-09-5

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 09730663.str

L1 STRUCTURE UPLOADED

=> sl1

SL1 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s l1

SAMPLE SEARCH INITIATED 09:57:35 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 34 TO ITERATE

100.0% PROCESSED 34 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 331 TO 1029

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 09:57:43 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 711 TO ITERATE

100.0% PROCESSED 711 ITERATIONS

20 ANSWERS

SEARCH TIME: 00.00.01

L3 20 SEA SSS FUL L1

=> FIL CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

140.28

140.49

FILE 'CAPLUS' ENTERED AT 09:57:49 ON 09 MAY 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 May 2002 VOL 136 ISS 19

FILE LAST UPDATED: 7 May 2002 (20020507/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s 13

L4 320 L3

=> s 14 and amorphous

208861 AMORPHOUS

L5 4 L4 AND AMORPHOUS

=> s 14 and celecoxib

386 CELECOXIB

L6 268 L4 AND CELECOXIB

=> d ibib abs hitstr 14 tot

L4 ANSWER 1 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:293418 CAPLUS

TITLE: Topical antibiotic composition for treatment of eye infection

INVENTOR(S): Bandyopadhyay, Rebanta; Secreast, Pamela J.; Hawley, Leslie C.; McCurdy, Vincent E.; Tyle, Praveen; Bandyopadhyay, Paramita; Singh, Satish K.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

Golam Shameem

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2000-17908 A 20000720
GB 2001-9648 A 20010419

OTHER SOURCE(S): MARPAT 136:129055


AB The invention provides a method of treating or preventing a disorder typified by an immunodeficiency (e.g. HIV), wherein the patient is administered a COX-2 inhibitor or deriv. or pharmaceutically acceptable salt thereof, preferably diisopropylfluorophosphate, L-745337, rofecoxib, NS 398, SC 58125, etodolac, meloxicam, celecoxib or nimesulide, as well as compns. and products contg. the same or use of the same in prepg. medicaments and for treatment.

IT 169590-42-5, Celecoxib

RL: AGR (Agricultural use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase 2 inhibitor for immunodeficiency condition treatment)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:84600 CAPLUS

DOCUMENT NUMBER: 136:151161

TITLE: Preparation of 4-(heterocyclyl)benzenesulfonamides as components of a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
INVENTOR(S): Isakson, Peter C.; Anderson, Gary D.; Gregory, Susan A.

PATENT ASSIGNEE(S): G. D. Searle & Co., USA


SOURCE: U.S., 19 pp., Cont.-in-part of U.S. Ser. No. 489,415, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6342510	B1	20020129	US 1996-661641	19960611
CA 2224563	AA	19961227	CA 1996-2224563	19960611
PRIORITY APPLN. INFO.:			US 1995-489415	B2 19950612
OTHER SOURCE(S):			MARPAT 136:151161	
GI				



AB The title compds. [I; A = (partially) unsatd. heterocyclyl or carbocyclyl; R1 = (un)substituted heterocyclyl, cycloalkyl, cycloalkenyl, aryl; R2 = Me, NH2; R3 = H, halo, alkyl, etc.] which are cyclooxygenase-2 inhibitors used in combination with a leukotriene B4 receptor antagonists for treatment of inflammation and inflammation-related disorders, were prepd. and formulated. Thus, treating Et trifluoroacetate with NaOMe in Me tert-Bu ether followed by addn. of 4'-chloroacetophenone (85%), and reacting the resulting 4,4,4-trifluoro-1-(4-chlorophenyl)butane-1,3-dione with 4-sulfonamidophenylhydrazine hydrochloride in EtOH afforded 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (80%).


IT **169590-42-5P**, 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 4-(1H-pyrazol-1-yl)benzenesulfonamides as antiinflammatories)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:74120 CAPLUS

DOCUMENT NUMBER: 136:272526

TITLE: COX-2 inhibition: A cautionary note in congestive heart failure

AUTHOR(S): Sica, Domenic A.; Schoolwerth, Anton C.; Gehr, Todd W. B.

CORPORATE SOURCE: Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA, 23298-0160, USA

SOURCE: Congestive Heart Failure (2000), 6(5), 272-276

CODEN: CHFAFZ

PUBLISHER: CHF, Inc.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. NSAIDs have been a mainstay of therapy for rheumatol. diseases for a no. of years. Unfortunately, their use was accompanied by sometimes unacceptable gastrointestinal and/or renal side effects. Therefore, safer treatment options were sought. In the process of such a search, selective cyclo-oxygenase-2 inhibitors were identified. Drugs in this class have anti-inflammatory properties similar to NSAIDs and did not produce anywhere near the same pattern of NSAID-related gastrototoxicity. The enthusiasm for this class of drugs would appear, at least on the surface, to be well grounded. However, establishing the renal side effect profile of the selective cyclo-oxygenase-2 inhibitors would appear to be a work in progress. Formal studies with selective cyclo-oxygenase-2 inhibitors have not been conducted in the congestive heart failure population. Information does though exist for other patient cohorts--similarly "prostaglandin-dependent" for their integrity of renal function, such as the elderly and sodium-deplete individual. These data would strongly suggest that the selective cyclo-oxygenase-2 inhibitors could decrease glomerular filtration rate and stimulate salt and water retention, comparable to what occurs with nonselective NSAIDs. To date, no compelling information exists, which supports the notion that differences exist among the currently available selective cyclo-oxygenase-2 inhibitors--celecoxib and rofecoxib--in the potential to neg. impact renal function in this and similarly compromised patient populations.


IT 169590-42-5, Celecoxib

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(COX-2 inhibitors impact on renal function in humans with congestive heart failure)


RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 320 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:71904 CAPLUS
 DOCUMENT NUMBER: 136:112699
 TITLE: Method of using cyclooxygenase 2 (COX-2) inhibitors in the treatment and prevention of ocular COX-2-mediated disorders
 INVENTOR(S): Bandyopadhyay, Rebanta; Eveleth, David; Van Haarlem, Tom; Kararli, Tugrul T.; Singh, Satish K.
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005848	A2	20020124	WO 2001-US14600	20010504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-218101P	P 20000713
			US 2001-279285P	P 20010328
OTHER SOURCE(S): MARPAT 136:112699				
AB The invention provides methods for the treatment and prevention of ocular COX-2-mediated disorders using COX-2 inhibitors, e.g. celecoxib.				
IT 169590-42-5 , Celecoxib				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(cyclooxygenase 2 inhibitors for treatment and prevention of ocular COX-2-mediated disorders)				
RN 169590-42-5 CAPLUS				
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)				



L4 ANSWER 19 OF 320 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:71873 CAPLUS
 DOCUMENT NUMBER: 136:123671
 TITLE: Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
 INVENTOR(S): Kararli, Tugrul T.; Bandyopadhyay, Rebanta; Singh, Satish K.; Hawley, Leslie C.
 PATENT ASSIGNEE(S): Pharmacia + Upjohn Company, USA
 SOURCE: PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005815	A1	20020124	WO 2001-US22061	20010712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002035264	A1	20020321	US 2001-904098	20010712
PRIORITY APPLN. INFO.:				
			US 2000-218101P	P 20000713
			US 2001-279285P	P 20010328
			US 2001-294838P	P 20010531
			US 2001-296388P	P 20010606

OTHER SOURCE(S): MARPAT 136:123671

AB A pharmaceutical compn. suitable for topical administration to an eye contains a selective COX-2 inhibitor or nanoparticles of a drug of low water soly., at a concn. effective for the treatment and/or prophylaxis of a disorder in the eye, and 1 or more ophthalmically acceptable excipients that reduce rate of removal from the eye such that the compn. has an effective residence time of 2-24 h. Also provided is a method of treating and/or preventing a disorder in an eye, the method comprising administering to the eye a compn. of the invention. Thus, an ophthalmic


nanoparticle suspension contained valdecoxib at 2.15 mg/g, 1.2% glycerin, 0.8% EDTA disodium salt, 4.0% Gelcarin GP-379NF, 0.21% SeaSpem PF and 0.82% Povidone.

IT 169590-42-5, Celecoxib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ophthalmic formulation of cyclooxygenase-2 inhibitor pharmaceuticals)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:71857 CAPLUS

DOCUMENT NUMBER: 136:139826

TITLE: Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain

INVENTOR(S): Hassan, Fred; Forbes, James C.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 218 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005799	A2	20020124	WO 2001-US22103	20010713
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-218101P	P 20000713
			US 2001-284248P	P 20010417

US 2001-296196P P 20010606

OTHER SOURCE(S): MARPAT 136:139826

AB A therapeutic combination useful in the treatment, amelioration, prevention, or delay of pain comprising a high energy form of a selective cyclooxygenase-2 inhibitor, a vasomodulator, and a pharmaceutically acceptable excipient, carrier, or diluent, the cyclooxygenase-2 inhibitor and vasomodulator each being present in an amt. effective to contribute to the treatment, prevention, or delay of pain. Thus, capsules contained celecoxib 200, Labrasol 280, diethylene glycol monoethyl ether 280, and propylene glycol laurate 140/capsule.


IT 169590-42-5, Celecoxib

RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cyclooxygenase-2 inhibitors and vasomodulators for generalized pain and headache pain treatment)

RN 169590-42-5 CAPLUS


CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030395	A1	20020418	WO 2001-US31590	20011010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-239136P	P 20001010
			US 2001-285340P	P 20010420
AB There is provided a pharmaceutical compn. suitable for topical administration to an eye, the compn. comprising as active agent one or more oxazolidinone antibacterial drugs, for example linezolid, in a concn. effective for treatment and/or prophylaxis of a gram-pos. bacterial infection of the eye, and one or more ophthalmically acceptable excipient ingredients that reduce rate of removal of the compn. from the eye by lacrimation such that the compn. has an effective residence time in the eye of about 2 to about 24 h. The compn. is, for example, an in situ gellable soln., suspension or soln./suspension. Formulations contg. a gelling or mucoadhesive agent (xanthan gum, HPMC, poloxamer 407, and polycarbophil) resulted in significant amts. of linezolid being retained in the exterior of treated eyes 1 h or more after application.				
IT INDEXING IN PROGRESS				
IT 169590-42-5, Celecoxib				
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical antibiotic compn. for treatment of eye infection)				
RN 169590-42-5 CAPLUS				
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)				



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 320 CAPLUS COPYRIGHT 2002 ACS

Golam Shameem

ACCESSION NUMBER: 2002:276519 CAPLUS
TITLE: Treatment of cancer with a prostate specific antigen (PSA) conjugate and an NSAID compound
INVENTOR(S): Heimbrook, David C.; Yao, Siu-long
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 129 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002042375	A1	20020411	US 2001-896245	20010629


PRIORITY APPLN. INFO.: US 2000-216217P P 20000705

AB The invention relates to methods of treating cancer using a combination of a compd. which is a PSA conjugate and a nonsteroidal antiinflammatory agent (NSAID) and to methods of prepg. such compns. The PSA conjugate comprises an oligopeptide that is selectively cleaved by PSA and a cytotoxic agent. An example of a PSA conjugate is N-Ac-(4-trans-L-Hyp)-Ala-Ser-Chg-Gln-Ser-Leu-Dox (Dox = doxorubicin, Hyp = hydroxyproline, Chg = cyclohexylglycine) and COX-2 inhibitor 3-phenyl-4-[4-(4-methylsulfonyl)phenyl]-2(5H)furanone is an example of an NSAID compd. (syntheses given).

IT **169590-42-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(treatment of cancer with prostate specific antigen (PSA) conjugate and NSAID compd.)

RN 169590-42-5 CAPLUS


CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 320 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:220369 CAPLUS
DOCUMENT NUMBER: 136:241665
TITLE: Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-V antagonist

INVENTOR(S): Hartman, George; Duggan, Mark; Rodan, Gideon A.;
 Rodan, Sevgi B.; Duong, Le T.; Kimmel, Donald B.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022124	A1	20020321	WO 2001-US42146	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002040039	A1	20020404	US 2001-955379	20010918
PRIORITY APPLN. INFO.:			US 2000-233609P	P 20000918
OTHER SOURCE(S):			MARPAT 136:241665	
AB The present invention provides for methods for treating or preventing an inflammatory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a cyclooxygenase-2 specific inhibitor in combination with an .alpha.V.beta.3, .alpha.V.beta.5, and/or .alpha.V.beta.6 integrin receptor antagonist in an amt. effective to treat or prevent the inflammatory disease or condition. The present invention also provides for pharmaceutical compns. for the treatment or prevention of an inflammatory disease or condition. Further, the invention provides for the manuf. of a medicament useful in the treatment or prevention of an inflammatory disease or condition.				
IT 169590-42-5 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (treatment of inflammation with a combination of a cyclooxygenase-2 inhibitors and an integrin-.alpha.V antagonists)				
RN 169590-42-5 CAPLUS CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)				





REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:212452 CAPLUS

DOCUMENT NUMBER: 136:210529

TITLE: Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo. [Erratum to document cited in CA133:202957]

AUTHOR(S): Takahashi, Yasushi; Roman, Christine; Chemtob, Sylvain; Tse, Mary M.; Lin, Emil; Heymann, Michael A.; Clyman, Ronald I.

CORPORATE SOURCE: Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, 94143-0544, USA

SOURCE: American Journal of Physiology (2000), 279(5, Pt. 2), No pp. given

CODEN: AJPHAP; ISSN: 0002-9513

PUBLISHER: American Physiological Society

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The accepted version of the In Vitro Studies section of METHODS is given to replace the earlier version that was published.

IT 169590-42-5, Celecoxib

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cyclooxygenase-2 inhibitors constrict fetal ductus arteriosus both in vitro and in vivo (Erratum))

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:184907 CAPLUS

DOCUMENT NUMBER: 136:241643

TITLE: Exemestane as chemopreventing agent

INVENTOR(S): Di Salle, Enrico; Piscitelli, Gabriella; Massimini, Giorgio; Purandare, Dinesh; Martini, Alessandro; Muggetti, Lorena

PATENT ASSIGNEE(S): Pharmacia + Upjohn S.p.A., Italy; Pharmacia + Upjohn Company

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020020	A1	20020314	WO 2001-EP10172	20010831
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				

PRIORITY APPLN. INFO.: US 2000-658052 A 20000908

AB The present invention concerns the use of aromatase inhibitor exemestane, either alone or in combination with other therapeutic agents, in the chemoprevention of estrogen dependent cancer in mammals, including humans, at increased risk of the disease. Exemestane treatment (4, 20 or 100 mg/kg/wk, IM), started 1 wk after dimethylbenzanthracene (DMBA) exposure (20 mg/rat, PO) and continued for 19 wk, significantly decreased tumor incidence from 85 % in vehicle treated rats to 13.6 % in the 100 mg/kg treated group. Moreover, exemestane at 100 mg/kg reduced significantly the tumor multiplicity, being 2.55 the no. of tumors/rat in the control groups vs. 0.27 in the treated group. No signs of toxicity were obsd.


IT **169590-42-5**, Celecoxib

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(in combination; exemestane as chemopreventing agent for
estrogen-dependent cancer)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:172487 CAPLUS

DOCUMENT NUMBER: 136:221745

TITLE: Irrigation solution and method for inhibition of pain and inflammation

INVENTOR(S): Demopulos, Gregory A.; Pierce-Palmer, Pamela; Herz, Jeffrey M.

PATENT ASSIGNEE(S): Omeros Medical Systems, USA

SOURCE: U.S. Pat. Appl. Publ., 58 pp., Cont.-in-part of Appl. No. PCT/US99/24625.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002028798	A1	20020307	US 2001-839633	20010420
WO 9619233	A2	19960627	WO 1995-US16028	19951212
WO 9619233	A3	19960919		
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5820583	A	19981013	US 1996-670699	19960626
US 6261279	B1	20010717	US 1998-72913	19980504
WO 2000023061	A2	20000427	WO 1999-US24557	19991020
WO 2000023061	A3	20001116		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				

CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 2000023062 A2 20000427 WO 1999-US24558 19991020
 WO 2000023062 A3 20000727
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 2000023066 A2 20000427 WO 1999-US24672 19991020
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 2000025745 A2 20000511 WO 1999-US26330 19991105
 WO 2000025745 A3 20000824
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.:
 US 1994-353775 B2 19941212
 WO 1995-US16028 A2 19951212
 US 1996-670699 A2 19960626
 US 1998-72913 A2 19980504
 US 1998-105026P P 19981020
 US 1998-105029P P 19981020
 US 1998-105044P P 19981020
 US 1998-105166P P 19981021
 US 1998-107256P P 19981105
 WO 1999-US24557 A2 19991020
 WO 1999-US24558 A2 19991020
 WO 1999-US24625 A2 19991020
 WO 1999-US24672 A2 19991020
 WO 1999-US26330 A2 19991105
 AB A method and soln. for perioperatively inhibiting a variety of pain and
 inflammation processes at wounds from general surgical procedures
 including oral/dental procedures. The soln. preferably includes at least
 one pharmacol. agent selected from the group consisting of a
 mitogen-activated protein kinase (MAPK) inhibitor, an .alpha.2-receptor

agonist, a neuronal nicotinic acetylcholine receptor agonist, a cyclooxygenase-2 (COX-2) inhibitor, a sol. receptor and mixts. thereof, and optionally addnl. multiple pain and inflammation inhibitory agents at dil. concn. in a physiol. carrier, such as saline or lactated Ringer's soln. The soln. is applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects assocd. with oral, i.m., s.c. or i.v. application of larger doses of the agents.


IT 169590-42-5, Celecoxib

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(irrigation soln. for inhibition of pain and inflammation at wounds during surgical procedures)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:171693 CAPLUS

DOCUMENT NUMBER: 136:221724

TITLE: Pharmaceutical compositions for topical delivery of cyclooxygenase-2 inhibitors

INVENTOR(S): Arora, Vinod Kumar; Singla, Ajay Kumar; Kumar, Mukesh

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002017923	A1	20020307	WO 2001-IB1557	20010828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2000-DE779 A 20000829


AB The present invention relates to a pharmaceutical compn. for topical delivery comprising a pharmaceutically effective amt. of drug(s) that acts selectively as a cyclooxygenase-2 enzyme inhibitor. Thus, a formulation contained celecoxib 3.0, Carbopol-940 1.0, PEG-400 15.0, propylene glycol 5.0, polyethylene glycol glyceryl caprylate 10.0, EtOH 10.0, triethanolamine 1.0, phenoxyethanol 1.0, fragrance (oil of lemon lime) 0.4, and water to 100%.

IT 169590-42-5, Celecoxib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. for topical delivery of cyclooxygenase-2 inhibitors)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 320 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:171666 CAPLUS
DOCUMENT NUMBER: 136:194271
TITLE: Prophylactic treatment of migraine
INVENTOR(S): Van Patten, Peter
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002017896	A2	20020307	WO 2001-US26797	20010827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				

US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-228851P P 20000829

OTHER SOURCE(S): MARPAT 136:194271


AB The present invention provides methods and compns. for the prophylactic, targeted prophylactic, acute or acutely targeted, or subacute treatment of migraine. Representative methods include an embodiment where a patient is regularly given a therapeutically effective amt. of a cyclooxygenase-2 inhibitor, an embodiment where a patient is co-administered a therapeutically effective amt. of a combination of a cyclooxygenase-2 inhibitor and acetylsalicylic acid and an embodiment where a patient is co-administered a therapeutically effective amt. of a combination of a cyclooxygenase-2 inhibitor and a 5-HT agonist. Representative compns. include cyclooxygenase-2 inhibitors, HT-5 agonists, acetylsalicylic acid and combinations thereof.

IT 169590-42-5, Celecoxib

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prophylactic treatment of migraine)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:157559 CAPLUS

DOCUMENT NUMBER: 136:205421

TITLE: Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor

INVENTOR(S): Karali, Tugrul T.; Kontny, Mark J.; Le, Tang T.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2002015886 A2 20020228 WO 2001-US25834 20010817

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002049233 A1 20020425 US 2001-932500 20010817

PRIORITY APPLN. INFO.:

US 2000-226347P P 20000818

OTHER SOURCE(S):

MARPAT 136:205421


AB An oral fast-melt compn. of a selective cyclooxygenase-2 inhibitory drug is prepd. by a process comprising a step of wet granulating the selective cyclooxygenase-2 inhibitory drug together with a binding agent selected from gums, polypeptides, natural and modified starches, cellulose materials, alginic acid and salts, polyethylene glycol, polyvinylpyrrolidone, polymethacrylates, silicate salts and bentonites, and a step of blending with the drug a saccharide of low moldability, wherein the above steps occur in any order or simultaneously to result in formation of granules. Optionally the process further comprises a step of blending the granules with at least 1 of a lubricant, a sweetening agent and a flavoring agent to form a tableting blend, and a step of compressing the tableting blend to form oral fast-melt tablets. Also provided is a compn. prepd. by such a process.

IT 169590-42-5, Celecoxib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral fast-melt dosage form of cyclooxygenase-2 inhibitor)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:157558 CAPLUS


DOCUMENT NUMBER: 136:205420

TITLE: Oral fast-melt formulation of a cyclooxygenase-2 inhibitor

INVENTOR(S): Le, Trang T.; Kararli, Tugrul T.; Kontny, Mark J.;
Sastry, Srikonda V.; Nyshadham, Janaki R.; Pagliero,
Arthur J., Jr.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA; Yamanouchi Technologies, Inc.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002015885	A2	20020228	WO 2001-US25803	20010817
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002049233	A1	20020425	US 2001-932500	20010817
PRIORITY APPLN. INFO.:			US 2000-226347P	P 20000818
OTHER SOURCE(S):	MARPAT 136:205420			
AB	An oral fast-melt compn. of a selective cyclooxygenase-2 inhibitory drug is prepd. by a process comprising a step of wet granulating the drug together with a binding agent comprising a saccharide of high moldability, and a step of blending with the drug a saccharide of low moldability, wherein the above steps occur in any order or simultaneously to result in formation of granules. The process optionally incorporates means to inhibit agglomeration of the drug, e.g., addn. of a wetting agent. Optionally the process further comprises a step of blending the granules with at least one of a lubricant, a sweetening agent and a flavoring agent to form a tableting blend, and a step of compressing the tableting blend to form oral fast-melt tablets. Also provided is a compn. prepd. by such a process. Thus, fast-melt tablets contained celecoxib 25.0, mannitol 66.75, maltose 5.0, Mg stearate 0.75, stearic acid 0.75, sodium lauryl sulfate 1.0, acesulfame-K 0.5, and spearmint flavor 0.25%.			
IT	169590-42-5, Celecoxib			
RL:	THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(oral fast-melt formulation of cyclooxygenase-2 inhibitor)			
RN	169590-42-5 CAPLUS			
CN	Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)			



L4 ANSWER 11 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:157557 CAPLUS

DOCUMENT NUMBER: 136:205419

TITLE: Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor

INVENTOR(S): Kararli, Tugrul T.; Kontny, Mark J.; Le, Trang T.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002015884	A2	20020228	WO 2001-US25762	20010817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-226487P P 20000818

OTHER SOURCE(S): MARPAT 136:205419

AB A molded article such as a tablet is provided for administration to an oral cavity of a subject to treat or prevent a cyclooxygenase-2 mediated condition, disorder or disease. The molded article comprises a moldable blend of a therapeutically effective amt. of a selective cyclooxygenase-2 inhibitory drug with an excipient carrier system consisting predominantly of 1 or more carbohydrates, wherein ingredients and amts. in the molded article and a process for prepg. the molded article are selected such that the molded article exhibits rapid disintegration in the oral cavity, and wherein the moldable blend is prepd. by a process step not requiring wet granulation.


IT 169590-42-5, Celecoxib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(rapidly disintegrating oral formulation of cyclooxygenase-2 inhibitor)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:132560 CAPLUS

DOCUMENT NUMBER: 136:288745

TITLE: Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy

AUTHOR(S): Rabeneck, Linda; Wristers, Kimberly; Goldstein, Jay L.; Eisen, Glenn; Dedhiya, Seema D.; Burke, Thomas A.
CORPORATE SOURCE: Department of Veterans Affairs Health Services Research and Development Center of Excellence and Department of Medicine, Baylor College of Medicine, Houston, TX, USA

SOURCE: American Journal of Gastroenterology (2002), 97(1), 32-39

CODEN: AJGAAR; ISSN: 0002-9270

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Objectives: We aimed to assess the Severity of Dyspepsia Assessment (SODA) scales as measures of change in dyspepsia-related health in a blinded, randomized, controlled trial in arthritis patients treated with nonsteroidal anti-inflammatory drugs. Methods: Three thousand nine hundred seven arthritis patients completed SODA at baseline and weeks 4, 13, 26, and 52 and/or at early termination. Using baseline and 4-wk data, reliability was evaluated with Cronbach's .alpha. and the intraclass correlation coeff. (ICC). Dyspepsia adverse events were defined based on a combined set of World Health Organization Adverse Reaction Terminol. terms. The ability of SODA to measure change in dyspepsia-related health was evaluated by comparing SODA change scores by dyspepsia adverse event severity level and withdrawal status. Responsiveness was further evaluated by the area under the curve (AUC) from receiver operating characteristic curves using withdrawal due to dyspepsia as the criterion. Results: The SODA scales - Pain Intensity (.alpha. = 0.93), Non Pain Symptoms (.alpha. = 0.82), and Satisfaction (.alpha. = 0.89) - demonstrated excellent internal consistency reliability using baseline data. Reproducibility was fair to good: Pain Intensity ICC = 0.49, Non Pain Symptoms ICC = 0.61, and Satisfaction ICC = 0.45. SODA change scores


(4-wk score - baseline score) increased, or worsened, with increasing dyspepsia severity and differentiated between adjacent levels of dyspepsia severity for eight of nine adjacent comparisons ($p < 0.05$). SODA change scores also differentiated between those who did and did not withdraw ($p < 0.001$). Responsiveness was highest with the Pain Intensity scale (AUC = 0.78), followed by the Non Pain Symptoms (AUC = 0.74) and Satisfaction (AUC = 0.75) scales. Conclusions: SODA is a reliable, valid instrument for use as a measure of dyspepsia tolerability in future clin. trials involving cyclo-oxygenase-2-specific and/or traditional nonsteroidal anti-inflammatory drugs.

IT 169590-42-5, Celecoxib

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (COX-2-specific inhibitor and traditional NSAID therapy in arthritic patients: dyspepsia as side effect)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:118614 CAPLUS

DOCUMENT NUMBER: 136:226250

TITLE: Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection

AUTHOR(S): Schonberger, Frank; Heinkele, Georg; Murdter, Thomas E.; Brenner, Stefanie; Klotz, Ulrich; Hofmann, Ute

CORPORATE SOURCE: Dr. Margarete Fischer-Bosch-Institut fur Klinische Pharmakologie, Stuttgart, D-70376, Germany

SOURCE: Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences (2002), 768(2), 255-260

CODEN: JCBAAI; ISSN: 1570-0232

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A simple method is described for the detn. of the cyclooxygenase-2 specific inhibitor celecoxib in human serum by HPLC using the demethylated analog as internal std. After protein pptn. with MeCN, samples were extd.

with CHCl₃. Sepn. was achieved on a Prontosil C18 AQ column (150.times.3 mm I.D., 3-.mu.m particle size) at a flow-rate of 0.35 mL/min using water-MeCN (40:60, vol./vol.) as the mobile phase. Using fluorescence detection with excitation at 240 nm and emission at 380 nm, the limit of quantification was 12.5 ng/mL for a sample size of 0.5 mL of serum. The assay was linear in the concn. range of 12.5-1500 ng/mL and showed good accuracy and reproducibility. At all concns. intra- and inter-assay variabilities were <11% with <9% error. The method was applied to the detn. of celecoxib for pharmacokinetic studies in man.


IT 169590-42-5, Celecoxib

RL: ANT (Analyte); PKT (Pharmacokinetics); ANST (Analytical study); BIOL (Biological study)

(simple and sensitive method for the detn. of celecoxib in human serum by high-performance liq. chromatog. with fluorescence detection)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:107158 CAPLUS

DOCUMENT NUMBER: 136:161365

TITLE: Aldosterone antagonist-cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders

INVENTOR(S): Rocha, Ricardo; Zack, Marc D.; McMahon, Ellen G.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 273 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009759	A2	20020207	WO 2001-US23601	20010726
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-221364P P 20000727

US 2001-261497P P 20010112

OTHER SOURCE(S): MARPAT 136:161365

AB Combinations of aldosterone blockers and Cyclooxygenase-2 inhibitors
useful in the treatment of inflammation-related cardiovascular disorders
are disclosed.


IT **169590-42-5**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(aldosterone antagonist-cyclooxygenase-2 inhibitor combination therapy
to prevent or treat inflammation-related cardiovascular disorders)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 320 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:89826 CAPLUS

DOCUMENT NUMBER: 136:129055

TITLE: Method using a cyclooxygenase 2 (COX-2) inhibitor for
treatment of an immunodeficiency condition

INVENTOR(S): Tasken, Kjetil; Moutschen, Michel; Rahmouni-Piette,
Souad; Aandahl, Einar Martin; Aukrust, Pal; Froland,
Stig S.; Johansson, Christian Carl; Hansson, Vidar;
Klaveness, Jo

PATENT ASSIGNEE(S): Lauras AS, Norway; Jones, Elizabeth Louise

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002007721	A2	20020131	WO 2001-GB3284	20010720

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:676581 CAPLUS

DOCUMENT NUMBER: 135:216023

TITLE: Micronized pharmaceutical sulfonamides or sulfones

INVENTOR(S): Reverchon, Ernesto

PATENT ASSIGNEE(S): Eco2 S.A., Switz.

SOURCE: PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066090	A1	20010913	WO 2001-CH131	20010301
W: AU, CA, CN, IL, JP, NZ, SG, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				

PRIORITY APPLN. INFO.: CH 2000-422 A 20000304


AB By means of the action of a supercrit. fluid (SCF), for example supercrit. carbon dioxide (SCCO2), substances of pharmaceutical use are pptd. in form of **amorphous** or semicryst. particles of micrometric or submicrometric dimensions. Said substances would most typically be sulfonamides or sulfones such as Nimesulide, dissolved in an org. solvent such as 1-methyl-2-pyrrolidone (NMP) or dimethylsulfoxide (DMSO). The process parameters are such as to maximize the soly. of the org. solvent in the SCF and minimize the soly. of the substance to be micronized in the SCF. The **amorphous** or semicryst. state of the particles so obtained, allow one to enhance the pharmacokinetics of the substance. For example, by means of the supercrit. antisolvent technique **amorphous** or semicryst. Nimesulide particles were produced. The substance was dissolved preferably in 1-methyl-2-pyrrolidone (NMP). The resulting soln. should possess a concn. of 0.1-100 mg/mL, preferably 10 mg/mL. The soln. was fed into the chamber at a flow rate of 0.1-10 mL/min, preferably at 1 mL/min, at a d. of 1100 kg/m3, in quantities ranging from 20 to 50 mL, preferably 30 mL. The antisolvent, preferably carbon dioxide, is fed into the chamber at a flow rate of 1000-10,000 mL (gas STP)/min, preferably at 8000 mL (gas STP)/min, at a pressure of 78-400 bar, preferably 85 bar, and at a temp. of 30-60.degree., preferably 40.degree.. The resulting ratio between flow rate of solvent and flow rate of antisolvent is 1.25 E-04. The product was finally washed by passing only antisolvent through the chamber for a period of time ranging from 60 to 100 min, preferably 80 min. The yield of recovered Nimesulide (300 mg) was > 95%.

IT 169590-42-5, Celecoxib

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(prepn. of micronized sulfonamides or sulfones by supercrit. fluid pptn.)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:435052 CAPLUS

DOCUMENT NUMBER: 135:37203

TITLE: Solid-state form of celecoxib having enhanced bioavailability

INVENTOR(S): Hageman, Michael J.; He, Xiaorong; Kararli, Tugrul T.; Mackin, Lesley A.; Miyake, Patricia J.; Rohrs, Brian R.; Stefanski, Kevin J.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042221	A1	20010614	WO 2000-US32435	20001206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1150959	A1	20011107	EP 2000-982255	20001206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002006951	A1	20020117	US 2000-730663	20001206
BR 2000008058	A	20020326	BR 2000-8058	20001206
NO 2001003855	A	20011005	NO 2001-3855	20010808
PRIORITY APPLN. INFO.:			US 1999-169856P	P 19991208
			WO 2000-US32435	W 20001206

AB The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in **amorphous** form. Also provided is a celecoxib-crystn. inhibitor composite comprising particles of **amorphous** celecoxib or a celecoxib drug substance of the invention in intimate assocn. with one or


more crystn. inhibitors, for example polymers. Also provided is a pharmaceutical compn. comprising such a celecoxib-crystn. inhibitor composite and one or more excipients. Celecoxib drug substance and polymer composites with HPMC and PVP were prepd. by spray drying. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a compn. of the invention in a therapeutically effective amt.

IT 169590-42-5, Celecoxib

RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(solid-state form of celecoxib having enhanced bioavailability)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:434782 CAPLUS

DOCUMENT NUMBER: 135:37187

TITLE: Solid-state form of celecoxib having enhanced bioavailability

INVENTOR(S): Hageman, Michael J.; He, Xiaorong; Kararli, Tugrul T.; Mackin, Lesley A.; Miyake, Patricia J.; Rohrs, Brian R.; Stefanski, Kevin J.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041536	A2	20010614	WO 2000-US30180	20001204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001020412 A5 20010618 AU 2001-20412 20001204

US 2002006951 A1 20020117 US 2000-730663 20001206

PRIORITY APPLN. INFO.:

US 1999-169856P P 19991208

WO 2000-US30180 W 20001204

AB The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in **amorphous** form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amt., as **amorphous** celecoxib. Also provided is a celecoxib-crystn. inhibitor composite comprising particles of **amorphous** celecoxib or a celecoxib drug substance of the invention in intimate assocn. with one or more crystn. inhibitors, for example polymers. Also provided is a pharmaceutical compn. comprising such a celecoxib-crystn. inhibitor composite and one or more excipients. Also provided are processes for prepg. **amorphous** celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystn. inhibitor composite of the invention, and a pharmaceutical compn. of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a compn. of the invention in a therapeutically effective amt.


IT 169590-42-5, Celecoxib

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(solid-state form of celecoxib having enhanced bioavailability)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:167780 CAPLUS

DOCUMENT NUMBER: 134:212732

TITLE: Coformulation of drugs and oligomeric or polymeric excipients

INVENTOR(S): York, Peter; Wilkins, Simon Anthony; Storey, Richard Anthony; Walker, Stephen Ernest; Harland, Ronald Scott

PATENT ASSIGNEE(S): Bradford Particle Design PLC, UK; Bristol-Myers Squibb

SOURCE: Company
PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015664	A2	20010308	WO 2000-GB3328	20000831
WO 2001015664	A3	20010920		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

GB 2355194	A1	20010418	GB 2000-21227	20000831
------------	----	----------	---------------	----------

PRIORITY APPLN. INFO.: GB 1999-20558 A 19990831


AB A coformulation of an active (preferably pharmaceutically active, for instance a COX-2 enzyme inhibitor) substance and an oligomeric or polymeric excipient, contg. at least 10% of the active, 80-100% of which is **amorphous**, is described. The **amorphous** phase is stable, with respect to the cryst. phase(s), for at least 3 mo after its prepn. when stored at 0-10.degree.. The invention also provides processes, preferably involving Soln. Enhanced Dispersion by Supercrit. fluids (SEDS) particle formation, for prepg. such a coformulation. For example, coformulations of glibenclamide and lactide-caprolactone copolymer (75:25) in ratios of 1:1 to 9:1 were successfully produced using SEDS and supercrit. nitrogen. The antisolvent flow rates were 15-25 L min⁻¹, those of the drug soln. in methylene chloride were 0.05-0.1 mL min⁻¹. Although the glibenclamide raw material was cryst., all of the SEDS products contained 100% **amorphous** drug phase.

IT **169590-42-5**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coformulation of drugs and oligomeric or polymeric excipients using SEDS technol.)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



=>

138

STN

09730663

Page 1

05/09/2002

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal626gms

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3 Jan 29 FSTA has been reloaded and moves to weekly updates
NEWS 4 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update
frequency
NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6 Mar 08 Gene Names now available in BIOSIS
NEWS 7 Mar 22 TOXLIT no longer available
NEWS 8 Mar 22 TRCTHERMO no longer available
NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/CAPLUS
and USPATFULL
NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12 Apr 08 "Ask CAS" for self-help around the clock
NEWS 13 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14 Apr 09 ZDB will be removed from STN
NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:56:06 ON 09 MAY 2002

Golam Shameem

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 08:56:17 ON 09 MAY 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 7 MAY 2002 HIGHEST RN 412267-09-5

DICTIONARY FILE UPDATES: 7 MAY 2002 HIGHEST RN 412267-09-5

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 09730663.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

Golam Shameem

=> s 11

SAMPLE SEARCH INITIATED 08:56:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 34 TO ITERATE

100.0% PROCESSED 34 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 331 TO 1029
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 sss full

FULL SEARCH INITIATED 08:57:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 711 TO ITERATE

100.0% PROCESSED 711 ITERATIONS
SEARCH TIME: 00.00.01

20 ANSWERS

L3 20 SEA SSS FUL L1

=> FIL CAPLUS

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
140.66	140.87

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 08:57:14 ON 09 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 May 2002 VOL 136 ISS 19
FILE LAST UPDATED: 7 May 2002 (20020507/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s 13

L4 32Q L3

=> d his

Golam Shameem

(FILE 'HOME' ENTERED AT 08:56:06 ON 09 MAY 2002)

FILE 'REGISTRY' ENTERED AT 08:56:17 ON 09 MAY 2002

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 20 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 08:57:14 ON 09 MAY 2002

L4 320 S L3

=> s 14 and celecoxib

L5 386 CELECOXIB
268 L4 AND CELECOXIB

=> s 15 and amorphous

208861 AMORPHOUS

L6 3 L5 AND AMORPHOUS

=> s 15 and crystalline

61140 CRYSTALLINE

162 CRYSTALLINES

61288 CRYSTALLINE

(CRYSTALLINE OR CRYSTALLINES)

287510 CRYST

1794 CRYSTS

288780 CRYST

(CRYST OR CRYSTS)

309640 CRYSTALLINE

(CRYSTALLINE OR CRYST)

L7 2 L5 AND CRYSTALLINE

=> d ibib abs hitstr 16 tot

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:676581 CAPLUS

DOCUMENT NUMBER: 135:216023

TITLE: Micronized pharmaceutical sulfonamides or sulfones

INVENTOR(S): Reverchon, Ernesto

PATENT ASSIGNEE(S): Eco2 S.A., Switz.

SOURCE: PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066090	A1	20010913	WO 2001-CH131	20010301
W: AU, CA, CN, IL, JP, NZ, SG, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				

PRIORITY APPLN. INFO.: CH 2000-422 A 20000304

AB By means of the action of a supercrit. fluid (SCF), for example supercrit. carbon dioxide (SCCO2), substances of pharmaceutical use are pptd. in form of **amorphous** or semicryst. particles of micrometric or submicrometric dimensions. Said substances would most typically be sulfonamides or sulfones such as Nimesulide, dissolved in an org. solvent such as 1-methyl-2-pyrrolidone (NMP) or dimethylsulfoxide (DMSO). The process parameters are such as to maximize the soly. of the org. solvent

in the SCF and minimize the soly. of the substance to be micronized in the SCF. The **amorphous** or semicryst. state of the particles so obtained, allow one to enhance the pharmacokinetics of the substance. For example, by means of the supercrit. antisolvent technique **amorphous** or semicryst. Nimesulide particles were produced. The substance was dissolved preferably in 1-methyl-2-pyrrolidone (NMP). The resulting soln. should possess a concn. of 0.1-100 mg/mL, preferably 10 mg/mL. The soln. was fed into the chamber at a flow rate of 0.1-10 mL/min, preferably at 1 mL/min, at a d. of 1100 kg/m³, in quantities ranging from 20 to 50 mL, preferably 30 mL. The antisolvent, preferably carbon dioxide, is fed into the chamber at a flow rate of 1000-10,000 mL (gas STP)/min, preferably at 8000 mL (gas STP)/min, at a pressure of 78-400 bar, preferably 85 bar, and at a temp. of 30-60.degree., preferably 40.degree.. The resulting ratio between flow rate of solvent and flow rate of antisolvent is 1.25 E-04. The product was finally washed by passing only antisolvent through the chamber for a period of time ranging from 60 to 100 min, preferably 80 min. The yield of recovered Nimesulide (300 mg) was > 95%.


IT 169590-42-5, Celecoxib

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(prepn. of micronized sulfonamides or sulfones by supercrit. fluid pptn.)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:435052 CAPLUS

DOCUMENT NUMBER: 135:37203

TITLE: Solid-state form of celecoxib having enhanced bioavailability

INVENTOR(S): Hageman, Michael J.; He, Xiaorong; Kararli, Tugrul T.; Macken, Lesley A.; Miyake, Patricia J.; Rohrs, Brian R.; Stefanski, Kevin J.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

Golam Shameem

applicant

FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042221	A1	20010614	WO 2000-US32435	20001206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1150959	A1	20011107	EP 2000-982255	20001206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002006951	A1	20020117	US 2000-730663	20001206
BR 2000008058	A	20020326	BR 2000-8058	20001206
NO 2001003855	A	20011005	NO 2001-3855	20010808
PRIORITY APPLN. INFO.:			US 1999-169856P	P 19991208
			WO 2000-US32435	W 20001206
AB	The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib -crystn. inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate assocn. with one or more crystn. inhibitors, for example polymers. Also provided is a pharmaceutical compn. comprising such a celecoxib -crystn. inhibitor composite and one or more excipients. Celecoxib drug substance and polymer composites with HPMC and PVP were prepd. by spray drying. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a compn. of the invention in a therapeutically effective amt.			
IT	169590-42-5, Celecoxib RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (solid-state form of celecoxib having enhanced bioavailability)			
RN	169590-42-5 CAPLUS			
CN	Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)			



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:434782 CAPLUS

DOCUMENT NUMBER: 135:37187

TITLE: Solid-state form of celecoxib having enhanced bioavailability

INVENTOR(S):

Hageman, Michael J.; He, Xiaorong; Kararli, Tugrul T.; Mackin, Lesley A.; Miyake, Patricia J.; Rohrs, Brian R.; Stefanski, Kevin J.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041536	A2	20010614	WO 2000-US30180	20001204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001020412	A5	20010618	AU 2001-20412	20001204
US 2002006951	A1	20020117	US 2000-730663	20001206
PRIORITY APPLN. INFO.:			US 1999-169856P	P 19991208
			WO 2000-US30180	W 20001204

AB The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amt., as amorphous celecoxib. Also provided is a celecoxib-crystn. inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate assocn. with one or more crystn. inhibitors, for example

polymers. Also provided is a pharmaceutical compn. comprising such a **celecoxib**-crystn. inhibitor composite and one or more excipients. Also provided are processes for prepg. **amorphous celecoxib**, a **celecoxib** drug substance of the invention, a **celecoxib**-crystn. inhibitor composite of the invention, and a pharmaceutical compn. of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a compn. of the invention in a therapeutically effective amt.


IT **169590-42-5, Celecoxib**

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(solid-state form of **celecoxib** having enhanced bioavailability)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



=> d ibib abs hitstr 17 tot

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:9967 CAPLUS

DOCUMENT NUMBER: 136:69810

TITLE: Preparation of a new **crystalline** form of **celecoxib**

INVENTOR(S): Guenduez, Halit; Bahar, Mehmet; Goektepe, Mehmet

PATENT ASSIGNEE(S): Fako Ilaclari A.S., Turk.

SOURCE: Eur. Pat. Appl., 14 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1167355	A1	20020102	EP 2001-106333	20010315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002016351	A1	20020207	US 2001-887354	20010622

WO 2002000627 A1 20020103 WO 2001-TR25 20010626


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: TR 2000-1872 A 20000626

AB The title **cryst.** form, characterized by x-ray spectral data, was
prepd.IT **169590-42-5P**RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of a new **cryst.** form of **celecoxib**)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:435053 CAPLUS

DOCUMENT NUMBER: 135:37174

TITLE: Polymorphic **crystalline** forms of
celecoxib

INVENTOR(S): Ferro, Leonard J.; Miyake, Patricia J.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042222	A1	20010614	WO 2000-US32760	20001201
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,			

LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1150960 A1 20011107 EP 2000-983865 20001201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

BR 2000008088 A 20020409 BR 2000-8088 20001201

US 2002006951 A1 20020117 US 2000-730663 20001206

NO 2001003868 A 20011003 NO 2001-3868 20010808

PRIORITY APPLN. INFO.: US 1999-169856P P 19991208

WO 2000-US32760 W 19991208

AB Pharmaceutical compns. are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory compd. of low water soly. in a therapeutically effective amt., wherein the compd. is present in the form of solid particles, 25-100% by wt. of which are <1 mm. The compns. are useful in treatment or prophylaxis of cyclooxygenase-2-mediated conditions and disorders and have particular advantages where rapid onset of therapeutic effect is desired. The novel Form I and Form II **cryst.** forms of **celecoxib** are described. The **cryst.** forms have unique chem. and phys. properties relative to other solid state forms of **celecoxib** and are characterized by their powder x-ray diffraction patterns, DSC thermograms, and other phys. characterizations. Thus, a DMF solvate of **celecoxib** was prepd. by the treatment of the drug (1 g) with 50 mL DMF. The solvent was slowly allowed to evap. to dryness when 1.0 g solvate (1:1) was obtained.


IT 169590-42-5DP, Celecoxib, polymorphs

284035-29-6P

RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process) (polymorphic **cryst.** forms of **celecoxib**)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 284035-29-6 CAPLUS


CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, compd. with N,N-dimethylformamide (1:1) (9CI) (CA INDEX NAME)

CM 1

Golam Shameem

CRN 169590-42-5


CMF C17 H14 F3 N3 O2 S



CM 2

CRN 68-12-2

CMF C3 H7 N O



IT 284035-28-5P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(polymorphic **cryst.** forms of **celecoxib**)


RN 284035-28-5 CAPLUS

CN Acetamide, N,N-dimethyl-, compd. with 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 169590-42-5


CMF C17 H14 F3 N3 O2 S



CM 2

CRN 127-19-5

CMF C4 H9 N O




IT 169590-42-5, Celecoxib

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(polymorphic **cryst.** forms of **celecoxib**)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logy

LOGY IS NOT A RECOGNIZED COMMAND

Golam Shameem

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

30.79

171.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.10

-3.10

STN INTERNATIONAL LOGOFF AT 09:03:11 ON 09 MAY 2002